Thanks to this Master's Degree, you will learn about the most advanced studies and research on cervical cancer and HPV” 

The human papillomavirus is behind many cancers of the cervix, vagina, vulva, penis, anus, rectum and oropharynx. Among them, cervical cancer, is especially worrying as one of the leading neoplasms to cause death in women around the world, especially in underdeveloped countries.  

Nevertheless, medical professionals have contributed through their daily communication and practice to curb the spread of HPV, while scientific studies have improved tests and diagnostic technology. This Professional Master's Degree offers an intensive and advanced update of knowledge thanks to the specialized teaching team on the program and the comprehensive syllabus that deals in depth with such essential elements as screening and the most recent and effective treatments for human papillomavirus. 

A program with a theoretical-practical approach that allows students to delve into the pathogenesis of HPV, the immune response, the effect of human papillomavirus in the anus, perianal and external genitalia, as well as the psychological impact it has on the person affected by this pathology. 

In this way, professionals will have at their disposal 10 complete Masterclasses designed by a teacher with extensive experience in the field of Gynecologic Oncology and with great international prestige. With this, graduates will update their clinical practice in the diagnosis and treatment of Gynecologic Cancer, thanks to the exclusive teaching materials that are at the forefront of technology and education. 

TECH thereby offers an excellent opportunity for professionals who wish to update their knowledge through a convenient and flexible teaching format. Students only need an electronic device to be able to connect at any time to the virtual campus where syllabus is hosted from day one. All of this, without attendance or classes with fixed schedules.  

Get up to date with TECH and learn more about the latest scientific findings in Gynecologic Cancer, thanks to 10 exclusive Masterclasses" 

This Master's Degree in Lower Genital Tract Pathology and HPV contains the most complete and up-to-date scientific program on the market. The most important features include:

• The development of practical cases presented by experts in Lower Genital Tract Pathology and HPV 
• The graphic, schematic and practical contents with which it is conceived provide scientific and practical information on those disciplines that are essential for professional practice
• Practical exercises where the self-assessment process can be carried out to improve learning
• Its special emphasis on innovative methodologies 
• Theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments
• Content that is accessible from any fixed or portable device with an Internet connection

The multimedia content of this program will take you in a visual and flexible way through the progress made in the approach to the patient suffering from cervical cancer" 

The program’s teaching staff includes professionals from the field who contribute their work experience to this educational program, as well as renowned specialists from leading societies and prestigious universities. 

The multimedia content, developed with the latest educational technology, will provide the professional with situated and contextual learning, i.e., a simulated environment that will provide immersive education programmed to prepare for real situations. 

This program is designed around Problem-Based Learning, whereby the professional must try to solve the different professional practice situations that arise during the course. For this purpose, the students will be assisted by an innovative interactive video system created by renowned and experienced experts.

This Master's Degree provides you with recent information, flexibility and freedom to study at your own pace"

This higher education program provides you with the highest scientific rigor in the latest therapies in the treatment of cervical injuries"

The most detailed and exhaustive information on Genital Tract Pathology and HPV is in the syllabus that has been prepared by the teaching team on this Master's Degree. An advanced syllabus, that will allow students to delve into the latest techniques in the detection of human papillomavirus, the treatments applied at present, and the care provided to pregnant patients with HPV or the use of vaccines for prevention. All this, complemented by specialized readings and interactive diagrams, which will help physicians to be up to date on this health area. 

A dynamic university program that allows you to delve into the prevalence of infection caused by the different types of HPV in the skin” 

Module 1. Pathogenesis of HPV and Immune Response: Intraepithelial Neoplasia 

1.1. Infection Routes 

1.1.1. Sexual Contact 
1.1.2. Objects 
1.1.3. In Medical Consultation 
1.1.4. Role of Condoms 
1.1.5. Vertical Transmission 
1.1.6. Protection of Surgeons during Vaporization 

1.2. Effect of the Immune System on HPV 

1.2.1. Innate Immunity and Adaptive Immunity 
1.2.2. General and Local Antibody Response 
1.2.3. Inhibition of the Immune Response 
1.2.4. Cellular Immunity against the Lesion 
1.2.5. Immunosenescence 

1.3. Viral Production and Genome Integration 

1.3.1. Difference between High and Low Risk Viruses 
1.3.2. Early and Late Gene Expression 
1.3.3. Viral Persistence and Quiescence 
1.3.4. Viral Clearance according to Age and Genotype 

1.4. Role of Vaginal Microbiota 

1.4.1. Definition of the Status Types of Bacteria Communities 
1.4.2. Relationship between Lesions and Different Types of Status 
1.4.3. Role of Lactobacilli on Immunity 

1.5. Development of Cervical Intraepithelial Neoplasms and Genital Warts 

1.5.1. Dysregulation of Cellular Mechanisms by Viral Proteins 
1.5.2. Progression 
1.5.3. Regression 
1.5.4. Relapse 

Module 2. The Human Papillomavirus: Characteristics and Epidemiology 

2.1. Structure and Composition of HPV 

2.1.1. General Description 
2.1.2. Capsid 
2.1.3. Genome 

2.2. Genetic Map of HPV and its Biological Functions 

2.2.1. Long Control Region 
2.2.2. Early Gene Expression 
2.2.3. Late Gene Expression 
2.2.4. Replicative Cycle 

2.3. Genotypes and their Clinical Importance 

2.3.1. Concept of High and Low Risk 
2.3.2. Low Risk Genotypes 
2.3.3. High Risk Genotypes 
2.3.4. Geographic Variations 

2.4. HPV Detection Techniques 

2.4.1. HPV Detection Techniques 
2.4.2. DNA-VPH Detection Technique with Hybrid Capture 
2.4.3. DNA-VPH Detection Technique with Partial Genotyping 
2.4.4. DNA-VPH Detection Technique with Complete Genotyping 
2.4.5. RNA Detection Techniques 
2.4.6. FDA Validation for Screening and Diagnosis 

2.5. Distribution of Genotypes in the World and in Our Environment 

2.5.1. Epidemiology in Relation to the Burden of Disease 
2.5.2. Geographic Variations 
2.5.3. Genotype Distribution in Spain BORRAR 

2.6. Prevalence According to Age 

2.6.1. In Women 
2.6.2. In Men 

2.7. Disease Burden of HPV 

2.7.1. Pathology Associated with Genital Infection in Women (Cervix, Vagina, Vulva) 
2.7.2. Pathology Associated with Genital Infection in Men (Scrotum, Penis and Gland) 
2.7.3. Pathology Associated with Anal Infection 
2.7.4. Pathology Associated with Oropharynx Infection 
2.7.5. Pathology Associated with Other Areas 

Module 3. Primary Prevention: Preventative Vaccines for Cervical Cancer

3.1. Characteristics of Available Vaccines

3.1.1. Divalent Vaccine
3.1.2. Tetravalent Vaccine
3.1.3. Nonavalent Vaccine
3.1.4. New Vaccines

3.2. Immunogenicity

3.2.1. Seroconversion and Antibody Level
3.2.2. Correlation between Antibody Level and Efficacy
3.2.3. Differences between the Available Vaccines and Possible Relevance
3.2.4. Estimation of the Protection Duration

3.3. Vaccine Efficacy and Effectiveness

3.3.1. Long-Term Efficacy Studies
3.3.2. Medium-Term Effectiveness Studies

3.4. Immunization in Special Groups

3.4.1. HIV+ Patients
3.4.2. Transplant Recipient
3.4.3. Immunosuppressed Patients
3.4.4. Men
3.4.5. Patients with VPH Lesions and/or Treated Patients

3.5. Safety of the Vaccine against HPV

3.5.1. Safety Profile
3.5.2. Most Frequent Adverse Events
3.5.3. Pharmacovigilance

3.6. Current Status of Vaccination in the World

3.6.1. Worlwide Vaccine Coverage
3.6.2. Vaccine Coverage in Spain BORRAR
3.6.3. Perspectives of Eradicating the Burden of Disease

Module 4. Cervical Cancer Screening

4.1. Screening

4.1.1. Concept
4.1.2. Need, Benefits and Limitations
4.1.3. Population Screening
4.1.4. Opportunist Screening
4.1.5. Health Care Screening

4.2. Cytology in Screening

4.2.1. Conventional Cytology
4.2.2. Liquid-Based Cytology
4.2.3. Automatic Cytology
4.2.4. Sensitivity and Specificity

4.3. HPV Test

4.3.1. Evidence on the Use of VPH in Screening
4.3.2. VPH as a Screening Test

4.3.2.1. Efficacy as a Primary Test
4.3.2.2. Efficacy as a Secondary Test
4.3.2.3. Most Efficient Screening Model with HPV

4.3.3. HPV Test Selection for Screening

4.4. Screening Strategies

4.4.1. Starting Age
4.4.2. Finishing Age
4.4.3. Screening Women Under 35
4.4.4. Screening Women Over 35
4.4.5. Special Population Screening

4.4.5.1. The Immunosuppressed
4.4.5.2. Screening in the Era of Vaccination

4.4.6. Population Screening in Spain. BORRAR Recommendations BORRAR

4.5. Other Complementary Techniques

4.5.1. Use of Viral Genotyping
4.5.2. Use of Biomarkers

4.6. Established Screening Systems and their Differences

4.6.1. Cytology as a Primary Strategy
4.6.2. VPH Test as a Primary Strategy
4.6.3. Biomarkers

Module 5. Dealing with Abnormal Screening Results

5.1. Action Protocols in the Event of an Abnormal Screening

5.1.1. Positive HPV Test
5.1.2. Altered Cytology

5.1.2.1. Non-Satisfactory
5.1.2.2. ASCUS
5.1.2.3. ASC-H
5.1.2.4. LSIL
5.1.2.5. HSIL
5.1.2.6. Atypical Cylindrical/Glandular Cells (AGC)

5.2. How to Establish a Correct Diagnosis?

5.2.1. The Importance of Using Up-to-Date Nomenclature
5.2.2. Use of Biomarkers as Characterization of Questionable Results

5.3. Management of Vaginal Microbiota in Treatment

5.3.1. Impact of Microbiota in Lesional Evolution
5.3.2. Use of Probiotics in during Monitoring

5.4. When to Treat and When to Continue? Management of Histological Results

5.4.1. LSIL
5.4.2. HSIL
5.4.3. The CIN 2 Enigma
5.4.4. Monitoring HSIL in Special Circumstances

5.5. Treatment of Cervical Lesions

5.5.1. Preference for Excisional Methods
5.5.2. Destructive Methods: Indications

5.6. Post-Treatment Monitoring

5.6.1. Post-Treatment HPV Determination
5.6.2. Monitoring Frequency

Module 6. Colposcopy

6.1. Colposcopy Terminology

6.1.1. Importance of Unified and Up-to-Date Terminology
6.1.2. Rio 2011 Terminology

6.2. How to Perform a Colposcopy?

6.2.1. Basic Concepts
6.2.2. Materials
6.2.3. Staining
6.2.4. Description of the Different Transformation Zones
6.2.5. Satisfactory Colposcopy
6.2.6. Unsatisfactory and Non-Adequate Colposcopy

6.3. Normal Findings

6.3.1. Original Squamous Epithelium
6.3.2. Glandular Epithelium, Ectopia
6.3.3. Squamous Metaplasia
6.3.4. Deciduous Cervix

6.4. Low Grade Pathological Findings

6.4.1. Weak Acetowhite Epithelium
6.4.2. Fine Punctation
6.4.3. Fine Mosaics

6.5. High-Grade Pathological Findings

6.5.1. Strong Acetowhite Epithelium, White on White
6.5.2. Coarse Punctation
6.5.3. Coarse Mosaics
6.5.4. Irregular Crypts
6.5.5. Other Suspicious Signs of High Grade

6.6. Normal and Abnormal Vascularization

6.6.1. Arboriform Structure Vessels
6.6.2. Pathological Vessels

6.7. Cancer Colposcopy

6.7.1. Necrosis
6.7.2. Exophytic Tumor
6.7.3. Bleeding Ulcers

6.8. Miscellaneous

6.8.1. Polyps
6.8.2. Leukoplakia.
6.8.3. Erosions
6.8.4. Iodonegativity

6.9. Colposcopy in Special Conditions

6.9.1. Colposcopy in Pregnancy
6.9.2. Colposcopy in Post-Treatment
6.9.3. Colposcopy in Menopausia

6.10. Vulvoscopy.

6.10.1. Description of the Lesion (Type, Colour and Secondary Morphology)
6.10.2. Miscellaneous Findings (Traumas and Deformities)
6.10.3. Malignant Suspicion (Ulcers, Exophytic Lesions, Necrosis, etc.)
6.10.4. Abnormal Magnified Findings

Module 7. Therapeutic Vaccines for Cervical Cancer

7.1. Biological Basis of Therapeutic Vaccines

7.1.1. Concept of Therapeutic Vaccines
7.1.2. Cytotoxicity Analysis of the Immune System
7.1.3. Target Antigens

7.2. Types of Therapeutic Vaccines

7.2.1. Based on Proteins and Peptides
7.2.2. Based on DNA
7.2.3. Based on Nanoparticles
7.2.4. Based on Cells

7.2.4.1. Activated Dendritic Cells
7.2.4.2. Processed Tumor Cells

7.2.5. Based on Bacterial Vectors and Living Viruses

7.3. Vaccines Against Low Grade Lesions

7.3.1. Design of Vaccine Against ASUS-LSIL
7.3.2. Clinical Trials and Results
7.3.3. Security/Safety

7.4. Vaccines Against High Grade Lesions

7.4.1. Design of Vaccine Against ASUS-LSIL
7.4.2. Clinical Trials and Results

7.5. Vaccines Against Cancer

7.5.1. Design of Vaccine Against ASUS-LSIL
7.5.2. Clinical Trials and Results
7.5.3. Immunotherapy

7.6. Safety of Therapeutic Vaccines

7.6.1. Safety Profile
7.6.2. Most Frequent Adverse Events
7.6.3. Vaccine Failure

7.7. Future of Therapeutic Vaccines

7.7.1. New Models
7.7.2. New Target Antigens
7.7.3. Other Ways of Stimulating the Immune System Against HPV

Module 8. Effect of HPV on the Anus and Perianal Area

8.1. Epidemiology of HPV Anal Infection

8.1.1. Disease Burden of HPV
8.1.2. Most Common Genotypes
8.1.3. Associated Precursor Lesions
8.1.4. Associated Tumoral Lesions

8.2. Natural History of HPV Anal Infection

8.2.1. Routes of Perianal Infection
8.2.2. Role of Anal Intercourse. Are these Important?
8.2.3. Associated Co-Factors
8.2.4. Condylomas
8.2.5. Viral Integration and Oncogenesis in the Anus and Perianal Area

8.3. Anal Intraepithelial Lesion

8.3.1. Development and Topography of Anal Lesion
8.3.2. Low Grade Lesions
8.3.3. High Grade Lesions

8.4. Screening of HPV Anal Lesion

8.4.1. The Role of Cytology
8.4.2. The Role of HPV Determination
8.4.3. Population Screening
8.4.4. Screening Strategies

8.5. Anuscopy

8.5.1. Anuscopy Technique
8.5.2. Normal Anuscopy and Benign Changes
8.5.3. Anuscopy with Low Grade Lesions
8.5.4. Anuscopy with High Grade Lesions
8.5.5. Anal Biopsy. Technique

8.6. Treatment of Anal and Perianal Lesion

8.6.1. Concept of Anal and Perianal Lesion Treatment
8.6.2. Treatment of Anal and Perianal Condylomas
8.6.3. Management of Anal and Perianal Intraepithelial Lesions
8.6.4. Medical Treatment
8.6.5. Surgical Management

8.7. Anus Cancer Due to HPV

8.7.1. Prevalence of Anus Cancer
8.7.2. Risk Factors
8.7.3. Symptoms
8.7.4. Diagnostic Techniques
8.7.5. Staging
8.7.6. Conservative Management
8.7.7. Radical Management. Anus Cancer Surgery
8.7.8. Monitoring After Treatment
8.7.9. Control/ Screening for VPH Infection in Other Areas

Module 9. Effect of HPV on the Oropharynx

9.1. Epidemiology of HPV Oropharynx Infection

9.1.1. Disease Burden of HPV
9.1.2. Topography of Oropharynx Lesions
9.1.3. Most Common Genotypes
9.1.4. Associated Precursor Lesions
9.1.5. Associated Tumoral Lesions

9.2. Natural History of HPV Oropharynx Infection

9.2.1. Routes of Oropharynx Infection
9.2.2. Role of Oral Sex
9.2.3. Associated Co-Factors
9.2.4. Oropharynx Condylomas
9.2.5. Viral Integration and Oncogenesis in the Oropharynx

9.3. Oropharynx Intraepithelial Lesion

9.3.1. Development and Topography of Oropharynx Lesion
9.3.2. Low Grade Lesions
9.3.3. High Grade Lesions

9.4. Screening of HPV Oropharynx Lesion

9.4.1. Role and Technique of Cytology
9.4.2. Role and Technique of HPV Determination
9.4.3. Population Screening
9.4.4. Screening Strategies

9.5. Visualization of the Types of Oropharynx Lesions Caused by HPV

9.5.1. Visualization Technique
9.5.2. Normal Oropharynx and Benign Changes
9.5.3. Oropharynx with Low Grade Lesions
9.5.4. Oropharynx with High Grade Lesions
9.5.5. Oropharynx Biopsy. Technique

9.6. Treatment of Oropharynx Lesions

9.6.1. Concept of Oropharynx Lesion Treatment
9.6.2. Treatment of Oropharynx Condylomas
9.6.3. Management of Oropharynx Intraepithelial Lesions
9.6.4. Medical Treatment
9.6.5. Surgical Management

9.7. Oropharynx Cancer Associated with HPV

9.7.1. Prevalence of Oropharynx Cancer
9.7.2. Risk Factors
9.7.3. Symptoms
9.7.4. Diagnostic Techniques
9.7.5. Staging
9.7.6. Conservative Management
9.7.7. Radical Management. Anus Cancer Surgery
9.7.8. Monitoring After Treatment
9.7.9. Control/ Screening for VPH Infection in Other Areas

Module 10. Effect of HPV on the External Genitals

10.1. Condylomas

10.1.1. Epidemiology and Burden of the Disease

10.1.1.1. Prevalence and Types of Vulvar Condylomas
10.1.1.2. Prevalence and Types of Vaginal Condylomas
10.1.1.3. Prevalence and Types of Condylomas on Male Genitals

10.1.2. Condyloma Risk Factors

10.1.2.1. Vulvar Condylomas
10.1.2.2. Vaginal Condylomas
10.1.2.3. Condylomas on Male Genitals

10.1.3. Screening for Cervical Lesions in Female External Genitalia Condylomas
10.1.4. Medical Treatment of Condylomas
10.1.5. Surgical Management

10.1.5.1. Ablative
10.1.5.2. Excisional

10.2. Vulval Intraepithelial Neoplasia (VIN)

10.2.1. Epidemiology and Burden of the Disease
10.2.2. Types of VIN
10.2.3. VIN Risk Factors
10.2.4. VIN Screening. Is it feasible?
10.2.5. VIN Management. Decision Algorithms
10.2.6. Expectant Treatment
10.2.7. Medical Treatment
10.2.8. Surgical Management

10.2.8.1. Ablative
10.2.8.2. Excisional

10.2.9. VIN Monitoring
10.2.10. Risk of Recurrence and Malignancy of VIN
10.2.11. Vulvar Cancer

10.3. Vaginal Intraepithelial Neoplasia

10.3.1. Epidemiology and Burden of the Disease
10.3.2. Types of VAIN
10.3.3. VAIN Risk Factors
10.3.4. VAIN Screening. Is it feasible?
10.3.5. VAIN Management. Decision Algorithms
10.3.6. Expectant Treatment
10.3.7. Medical Treatment
10.3.8. Surgical Management

10.3.8.1. Ablative
10.3.8.2. Excisional

10.3.9. VAIN Monitoring
10.3.10. Risk of Recurrence and Malignancy of VAIN
10.3.11. Vagina Cancer

10.4. Premalignant Lesions in Male External Genitals (PIN)

10.4.1. Epidemiology and Burden of the Disease
10.4.2. Types of PIN
10.4.3. PIN Risk Factors
10.4.4. PIN Screening. Is it feasible?
10.4.5. PIN Management. Decision Algorithms
10.4.6. Expectant Treatment
10.4.7. Medical Treatment
10.4.8. Surgical Management

10.4.8.1. Ablative
10.4.8.2. Excisional

10.4.9. PIN Monitoring
10.4.10. Risk of Recurrence and Malignancy of PIN
10.4.11. Penile Cancer

Module 11. Cervical Cancer (CC)

11.1. Epidemiology and Risk Factors of CC Development

11.1.1. Worldwide Incidence and Mortality of CC
11.1.2. Incidence and Mortality of CC per Region and Country
11.1.3. Incidence and Mortality of CC in Spain BORRAR
11.1.4. Tobacco and CC
11.1.5. Hormonal Contraception and CC
11.1.6. Effect of IDU on the Incidence of CC
11.1.7. Diet and CC
11.1.8. Sexually Transmitted Infections and Risk of CC
11.1.9. Parity and CC
11.1.10. Age of Starting Sexual Relations and Promiscuity.
11.1.11. Couples At-Risk. Male Circumcision and CC

11.2. Staging and Techniques of Extension

11.2.1. Diagnosis through Biopsy or Conization
11.2.2. FIGO and TNM Stages
11.2.3. Transvaginal Ultrasound Assessment in the Diagnosis of Extension
11.2.4. Magnetic Resonance Assessment in the Diagnosis of Extension
11.2.5. Tumor Markers Assessment
11.2.6. Clinical Staging vs. Post-Surgical vs. Imaging

11.3. Basis of CC Treatment

11.3.1. Conization as a Treatment. When It Is Indicated
11.3.2. Types of Radical Hysterectomy
11.3.3. Complications of the Different Types of Radical Hysterectomy
11.3.4. Sentinel lymph node
11.3.5. Para-Aortic Lymphadenectomy
11.3.6. External Radiotherapy and Brachytherapy
11.3.7. Chemotherapy

11.4. Routes of Surgical Treatment

11.4.1. Laparotomy
11.4.2. Laparoscopy
11.4.3. Robotics
11.4.4. LACC Studies: Open vs. Minimally Invasive

11.5. Treatment Plans

11.5.1. Decision Algorithms
11.5.2. Treatment in Initial Stages

11.5.2.1. Conization as a Treatment
11.5.2.2. Need for Radicalism
11.5.2.3. Parametrectomy in Previous Hysterectomy

11.5.3. Treatment in Advanced Stages

11.5.3.1. Role of Para-Aortic Lymphadenectomy
11.5.3.2. Para-Aortic Lymphadenectomy Access and Routes
11.5.3.3. Role of PET-CT Against Para-Aortic Lymphadenectomy

11.5.4. Vaccine Therapies Against Cervical Cancer
11.5.5. CCU Monitoring

11.6. Fertility Preservation Treatment

11.6.1. Indications of Fertility Preservation
11.6.2. Expectant Care After Conization
11.6.3. Simple and Radical Trachelectomy
11.6.4. Most Appropriate Approach of Trachelectomy

11.6.4.1. Open
11.6.4.2. Vaginal
11.6.4.3. Laparoscopy
11.6.4.4. Robotics

11.7. Alternative Therapies in Local Advanced CC

11.7.1. Chemoradiotherapy.
11.7.2. Role of New Chemotherapies
11.7.3. Immunotherapy

Module 12. Psychological Impact of HPV Infection 

12.1. Effect of HPV on the Individual 

12.1.1. Response of Individual After Finding Out They Have HPV 
12.1.2. Physiological Reactions to HPV Infection 
12.1.3. Pathological Reactions to HPV Infection 
12.1.4. Individual Sense of Guilt
12.1.5. Effect on Sexual Activity 
12.1.6. Management of Psychological Alterations 
12.1.7. Access to Information on Social Media and the Internet 

12.1. 8 Associations Affected by HPV 
12.2. Effect in HPV on the Partner 

12.2.1. Response of the Partner After Finding Out They Have HPV 
12.2.2. Physiological Reactions of the Partner to HPV Infection 
12.2.3. Pathological Reactions of the Partner to HPV Infection 
12.2.4. Behavior Towards Sexual Relations with the Partner 
12.2.5. Management of Changes in the Couple’s Relationship 
12.2.6. Preventative Behavior of the Infection and its Repercussions on Couple Sex Life 

12.3. Sexual Activity after HPV 

12.3.1. Psychological Stages after Finding Out They Have HPV 
12.3.2. Consequences on Sexual Behavior 
12.3.3. Breakup of the Couple 
12.3.4. When Only One in the Couple is Infected 
12.3.5. When Both are Infected 
12.3.6. Behaviors of the Infected Individual or Partner with Members of their Environment 
12.3.7. Sexual Orientation of the Infected Couple 

12.4. Depression and Mood Alterations after HPV 

12.4.1. Prevalence of Depressive Syndromes in Those Infected with HPV 
12.4.2. Effect of HPV on an Individual’s Depression 
12.4.3. Management of Depressive Syndromes Caused by HPV 
12.4.4. Management of Psychotic Syndromes Caused by HPV 
12.4.5. Management of Obsessive Syndromes Caused by HPV 

12.5. Individual Psychological Management 

12.5.1. Professional Attitude Towards a Patient with HPV 
12.5.2. How to Explain HPV Infection? 
12.5.3. Cognitive-Behavioral 
12.5.4. Group Therapy 
12.5.5. Drug Therapy 

12.6. Couple Psychological Management 

12.6.1. Professional Attitude Towards the Partner of a Patient with HPV 
12.6.2. How to Explain HPV Infection to the Partner of an HPV Patient? 
12.6.3. Professional Attitude Towards the Breakup of the Couple  
12.6.4. Couples Therapy. Reinventing Sex 
12.6.5. Adjuvant Drug Therapy

12.7. Desire to get Pregnant with HPV Infection 

12.7.1. Professional Attitude Towards the Desire to get Pregnant of a Patient with HPV 
12.7.2. Recommendations for Indicating Pregnancy 
12.7.3. When Pregnancy Should Be Contraindicated? 
12.7.4. Monitoring During the Period of Trying to Get Pregnant 
12.7.5. Attitude of the Partner During Pregnancy 
12.7.6. Psychological Alterations That Occur During the Period of Trying to Get Pregnant 

Module 13. Special Conditions in HPV Infection 

13.1. Pregnancy 

13.1.1. Prevalence of HPV in Pregnant Women 
13.1.2. Natural History of HPV Infections in Pregnant Women 
13.1.3. Colposcopy during Pregnancy 
13.1.4. Condylomas and Pregnancy. Multiple Condylomatosis 
13.1.5. Control of Cervical Lesions during Pregnancy 
13.1.6. Transmission to the Neonatal During the Birth 
13.1.7. Evolution and Viral Clearance after Delivery 
13.1.8. Management of HPV Lesions During Pregnancy 

13.2. Immunosuppression 

13.2.1. Prevalence of HPV in Immunosuppressed Patients 
13.2.2. Natural History of HPV Infections in Immunosuppressed Patients 
13.2.3. Colposcopy in Immunosuppressed Women 
13.2.4. Vulvar Condylomas and their Management. Multiple Condylomatosis 
13.2.5. Screening of HPV Cervical Lesions in Immunosuppression 
13.2.6. Vaccination of Immunosuppressed Patients 
13.2.7. Evolution of Lesions for Immunosuppressed Patients and Viral Clearance 
13.2.8. Management of HPV Lesions in Immunosuppressed Patients 

13.3. AIDS 

13.3.1. Prevalence of HPV in AIDS 
13.3.2. Natural History of VPH Infections in AIDS 
13.3.3. Colposcopy in Women with AIDS 
13.3.4. Vulvar Condylomas and their Management AIDS 
13.3.5. Vaccination Against HPV in AIDS 
13.3.6. Screening of HPV Cervical Lesions in AIDS 
13.3.7. Evolution of Lesions for Immunosuppression in AIDS. Accumulative Effect of Both Viruses 
13.3.8. Management of HPV Lesions in AIDS 

13.4. Skin Infections From HPV 

13.4.1. Prevalence of Skin Infections in the Different Types of HPV 
13.4.2. Topography of Dermal HPV Lesions 
13.4.3. Natural History of VPH Infections in the Skin 
13.4.4. Dermal Warts of Viral Origin 
13.4.5. Prevention of Dermal Conditions from HPV 
13.4.6. Management of Dermal HPV Lesions 

13.5. Associated Sexually Transmitted Infections 

13.5.1. Prevalence of STIs 
13.5.2. Association Between HPV and STIs 
13.5.3. Natural History of VPH-STI Co-Infections. Individual or Cumulative Effect 
13.5.4. Prevention of STIs 
13.5.5. Colposcopy and Vulvoscopy of STIs 
13.5.6. Management of STIs 

13.6. Uncommon Infections From HPV 

13.6.1. Distribution of HPV Genotypes 
13.6.2. Tropism of HPV Genotypes 
13.6.3. Low Prevalence HPV-Associated Conditions 
13.6.4. Management of Low Prevalence HPV Lesions 

13.7. Neonatal Infection from HPV and Recurrent Laryngeal Papillomatosis in Neonates 

13.7.1. Prevalence of Neonatal Conditions from HPV 
13.7.2. Consequences of HPV Infections in Newborns 
13.7.3. Management of HPV Neonatal Infection 
13.7.4. Recurrent Laryngeal Papillomatosis. Natural History 
13.7.5. Treatment of Recurrent Laryngeal Papillomatosis 

13.8. Infections From HPV in Children 

13.8.1. Prevalence of Conditions from HPV in Children 
13.8.2. Consequences of HPV Infections in Children 
13.8.3. Management of HPV Infection in Children 
13.8.4. Legal Considerations of Infections From HPV in Children 

A unique, key and decisive opportunity for your professional development”